Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 11/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19821237 | 1.00 | BTN3A1 (0.47) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL19825413 | 1.00 | BTN3A1 (0.47) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510991 | 0.95 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2510990 | 0.95 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2549985 | 0.95 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2521573 | 0.95 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL2512431 | 0.95 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL850195 | 0.95 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL16081101 | 0.95 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL30208193 | 0.95 | BTN3A1 (0.50) | BTN3A1CYP3A4CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | IVACHTCHENKO ALEXANDRE VASILIEVICH (US) | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030080-A1 | Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use | HCCS, NTPCR, NSUN2 | BTN3A1 2761/4885CYP3A4 268/4885CYP2C9 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.